SRR23303772
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.460
- HEDGEHOG_SIGNALING+0.300
- APICAL_JUNCTION+0.260
- P53_PATHWAY+0.260
- MYC_TARGETS_V2+0.220
- NOTCH_SIGNALING+0.220
- TGF_BETA_SIGNALING+0.210
- ESTROGEN_RESPONSE_EARLY+0.200
- MYOGENESIS+0.190
- ANGIOGENESIS+0.140
Top 10 suppressed
- E2F_TARGETS-0.480
- PROTEIN_SECRETION-0.480
- G2M_CHECKPOINT-0.430
- MTORC1_SIGNALING-0.380
- MYC_TARGETS_V1-0.360
- SPERMATOGENESIS-0.340
- OXIDATIVE_PHOSPHORYLATION-0.330
- PANCREAS_BETA_CELLS-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.310
- ANDROGEN_RESPONSE-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R109 | — | — | 0.833 |
| 2 | SRR4195667 | — | — | 0.829 |
| 3 | SRR33532763 | — | D | 0.807 |
| 4 | MBCProject_3672_T1_RNA | — | B | 0.798 |
| 5 | R7 | — | — | 0.795 |
| 6 | DRR168571 | — | — | 0.791 |
| 7 | R168 | — | — | 0.785 |
| 8 | SRR4195649 | — | — | 0.785 |
| 9 | SRR12475127 | — | — | 0.773 |
| 10 | TCGA-A2-A4RY-01A-31R-A266-07 | — | A | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.460 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |